Neurology and Other
Our comprehensive portfolio of well-established specialty pharmaceuticals targets neurological diseases such as epilepsy, migraines, depression, chronic pain, Huntington's disease, Parkinson's disease and orphan diseases. Valeant's Neurology and Other product portfolio offers hope for relief to patients suffering from these conditions.
Valeant's key neurology products are Wellbutrin® XL, a once-daily formulation of bupropion for the treatment of depression and seasonal affective disorder; Cesamet®, an oral antiemetic for chemotherapy-induced nausea; Diastat®, a benzodiazepine anticonvulsant; Nitoman® (tetrabenazine) for the treatment of hyperkinetic movement disorders, including chorea associated with Huntington's disease, and Xyrem®, a central nervous system (CNS) depressant. In the field of pain management, key products are Onsolis, a fentanyl citrate buccal soluble film for the treatment of breakthrough cancer pain, and Ralivia®, a once-daily formulation of tramadol for the treatment of chronic pain.
In May 2010, Valeant acquired Aton Pharma, Inc., a specialty pharmaceutical company focused on ophthalmology and certain orphan drug indications, located in Lawrenceville, New Jersey. This acquisition significantly enhances Valeant's neurology and other products franchise in the United States with both an in-line business and a development pipeline consisting primarily of orphan drug compounds. The acquisition of Aton fits into Valeant's long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers another platform for future growth.